AstraZeneca investment to increase biologic capacity in Sweden

AstraZeneca has announced the largest single investment in its Sweden Biomanufacturing Center in Södertälje, since the facility opened in 2021.

The additional $135 million investment will increase the biopharmaceutical facility area by 50 percent.